Literature DB >> 15906699

Newborn screening: experience of Bangladesh.

Fauzia Moslem1, Sufia Yasmeen, Mizanul Hasan, M A Karim, Nurun Nahar, Anindita Ahmed.   

Abstract

Newborn screening for early diagnosis of many preventable diseases is already an established program in developed countries as well as in some countries in Asia. With the control of infectious and communicable diseases, the Bangladesh government is now giving more attention to the preventive aspect of health. The country is now preparing to adopt newborn screening as part of the preventive aspect of health. Among the various activities are laboratory set up, expert visits, pilot studies on CH and training of personnel. A national project to screen newborns for congenital hypothyroidism is now under active consideration. A universal newborn screening program is a highly ambitious project for a country like Bangladesh. Funds to run such a program will be the main problem. The social pattern where still more than 80% of deliveries are done at home is another constraint. However, the enthusiasm of the professionals as well as of the government is a very encouraging thing. Now it needs the support of the international communities.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15906699

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  2 in total

1.  Newborn screening in the Asia Pacific region.

Authors:  Carmencita D Padilla; Bradford L Therrell
Journal:  J Inherit Metab Dis       Date:  2007-07-23       Impact factor: 4.982

2.  Incidental screen positive findings in a prospective cohort study in Matlab, Bangladesh: insights into expanded newborn screening for low-resource settings.

Authors:  Malia S Q Murphy; Pranesh Chakraborty; Jesmin Pervin; Anisur Rahman; Lindsay A Wilson; Monica Lamoureux; Kathryn Denize; Matthew Henderson; Steve Hawken; Beth K Potter; Julian Little; Kumanan Wilson
Journal:  Orphanet J Rare Dis       Date:  2019-01-30       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.